Last reviewed · How we verify

NCT06551402

Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis

Recruiting now Phase 3 Last updated 13 August 2024
What this trial tests

Phase 3 trial testing Dabigatran Etexilate 150mg in Cerebral Venous Sinus Thrombosis in 200 participants. Currently enrolling.

Timeline
9 August 2024
Primary endpoint
1 October 2026
1 November 2026

Quick facts

Lead sponsorKafrelsheikh University
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment200
Start date9 August 2024
Primary completion1 October 2026
Estimated completion1 November 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Kafrelsheikh University

Who can join

Adults 18 to 75, any sex, with Cerebral Venous Sinus Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dabigatran Etexilate 150mg

Trials testing the same drug.

Other recruiting trials for Cerebral Venous Sinus Thrombosis

Currently open trials in the same condition.

Other Kafrelsheikh University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06551402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing